Drug Trial Radar · NCT07503756
JS212 Combination Therapies in Metastatic Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Apr 25, 2026
Primary completion
Dec 30, 2027
Study completion Mar 30, 2028
Sponsor
- Lead sponsor
- Shanghai Junshi Bioscience Co., Ltd.Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 31, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter Phase 2 clinical study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of JS212-based combination therapies in patients with metastatic colorectal cancer (mCRC). JS212 is a bispecific antibody-drug conjugate (ADC) targeting epidermal growth factor receptor (EGFR) and HER3 with a topoisomerase I inhibitor payload. Preclinical and early clinical data suggest that dual targeting of EGFR and HER3 may enhance antitumor activity and overcome resistance mechanisms associated with EGFR- or HER2-directed therapies. This study will investigate JS212 in combination with capecitabine, with or without Bevacizumab, and JS212 in combination with chemotherapy (XELOX: capecitabine and oxaliplatin), with or without the PD-1/VEGF bispecific antibody JS207, in patients with mCRC. The study will assess safety, determine the recommended Phase 3 dose (RP3D), and evaluate preliminary antitumor activity of the combination regimens.
Conditions
- Metastatic Colorectal Cancer
Interventions
JS212Drug
Bispecific antibody-drug conjugate targeting EGFR and HER3
CapecitabineDrug
Oral fluoropyrimidine chemotherapy
BevacizumabDrug
Humanized anti-VEGF monoclonal antibody
OxaliplatinDrug
Platinum-based chemotherapy administered intravenously
JS207Drug
Bispecific antibody targeting PD-1 and VEGF
Primary outcomes
What the sponsor says the trial is designed to measure.
- Investigator-assessed objective response rate (ORR)Time frame: Up to approximately 12 months
- Safety and Tolerability(AEs)Time frame: From first dose up to approximately 90 days after last dose
- Safety and Tolerability(SAEs)Time frame: From first dose up to approximately 90 days after last dose
- Safety and Tolerability(DLTs)Time frame: From first dose up to approximately 90 days after last dose
- Maximum Tolerated Dose (MTD)Time frame: Up to approximately 6 months
- Recommended Phase 3 Dose (RP3D)Time frame: Up to approximately 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai East Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.